Award
NIH Reporter #5R01AI193221-02
A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia
Recipient
ABVACC, INC.
Award Amount
$642,054.00
Ceiling
$642,054.00
Awarded
September 17, 2026
Identifier
5R01AI193221-02
NIH grant awarded by NIAID for a 5-year project to develop immunotherapy against Staphylococcus aureus bacteremia, including MRSA, involving antibody identification, structural analysis, and animal model testing.
Description
The project focuses on developing immunotherapeutic antibodies against Staphylococcus aureus, including MRSA. The project involves multiple aims including identifying monoclonal antibodies, structural analysis, and efficacy testing in animal models. The funding is provided by NIAID, part of NIH. The project duration is approximately 5 years.